
Human CMV pp65 198-206, VVCAHELVC
Description
About Human CMV pp65 198-206, VVCAHELVC
The Human Cytomegalovirus (HCMV) (strain AD169) 65 kDa phosphoprotein (pp65) Peptide (IEDB: 71613) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The 65 kDa phosphoprotein (pp65) Peptide, H-VVCAHELVC-OH (Uniprot: P06725 aa: 198-206) from JPT is produced under strict quality control and quality management.
Human CMV pp65 198-206, VVCAHELVC - Specifications
- Peptide sequence: H-VVCAHELVC-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Infection
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Request a Quote for you custom antigen peptide!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human CMV pp65 198-206, VVCAHELVC
References:
Read References with JPT’s Antigen Peptides
Human CMV pp65 198-206, VVCAHELVC has been described in:
Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles., Blood, 2004 (PMID: 12947002)
Cytomegalovirus-Specific T Cells Restricted by HLA-Cw*0702 Increase Markedly with Age and Dominate the CD8<sup>+</sup> T-Cell Repertoire in Older People., Front Immunol, 2017 (PMID: 29312307)
Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes., Cancer Immunol Immunother, 2016 (PMID: 27600516)
Documentation
Documentation for Human CMV pp65 198-206, VVCAHELVC
Properties
Properties of Human CMV pp65 198-206, VVCAHELVC
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Infection |
Layout: | Freeze-dried in glass vial |
Organism: | Human Cytomegalovirus (HCMV) |
Protein Name: | 65 kDa phosphoprotein (pp65) |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human CMV pp65 198-206, VVCAHELVC
Information | Values |
---|---|
Sequence: | H-VVCAHELVC-OH |
Specifications: | 9mer peptide as TFA salt |